VIVEbiotech wraps up its participation at ISCT 2026
A successful event strengthening connections in the cell & gene therapy community
On the final day of the International Society for Cell & Gene Therapy (ISCT) 2026, held from May 6–9 at The Convention Centre Dublin (CCD), VIVEbiotech concludes several days of valuable exchanges with partners, collaborators, and key players in the sector.
Throughout the event, the VIVEbiotech team has showcased its capabilities in lentiviral vector development and manufacturing, supporting projects from early stages through to commercialization, for both ex-vivo and in-vivo applications.
Representing the company on-site are Maria Echeverria, Head of Upstream Development, and Miguel Álvarez, Business Development Manager, who continue to engage with industry professionals and explore new collaboration opportunities during this last day of the event.
One of the highlights of the final day was the ISCT 5K Run, where part of our team took part in an energizing networking activity across the city.
Later today, our team will attend the ISCT Gala Dinner, an excellent opportunity to continue conversations, exchange ideas, and strengthen relationships within the global cell and gene therapy community.
Beyond the conference, tomorrow Maria and Miguel will also participate in several thought leadership events, continuing insightful discussions and staying at the forefront of innovation in advanced therapies.
ISCT once again serves as a key meeting point for innovation and partnership in advanced therapies. As the event comes to a close today, VIVEbiotech encourages attendees to take the opportunity to connect in person and continue building future collaborations.